Elsevier

Lung Cancer

Volume 159, September 2021, Pages 117-126
Lung Cancer

Considerable interlaboratory variation in PD-L1 positivity in a nationwide cohort of non-small cell lung cancer patients

https://doi.org/10.1016/j.lungcan.2021.07.012Get rights and content
Under a Creative Commons license
open access

Highlights

  • Considerable variation in PD-L1 positivity exists between pathology laboratories.

  • Variation is greatest when PD-L1 positivity is determined according to the 1% cutoff.

  • This variation could negatively influence treatment decisions for NSCLC patients.

Abstract

Objectives

Immunohistochemical expression of programmed death-ligand 1 (PD-L1) is used as a predictive biomarker for prescription of immunotherapy to non-small cell lung cancer (NSCLC) patients. Accurate assessment of PD-L1 expression is therefore crucial. In this study, the extent of interlaboratory variation in PD-L1 positivity in the Netherlands was assessed, using real-world clinical pathology data.

Materials and Methods

Data on all NSCLC patients in the Netherlands with a mention of PD-L1 testing in their pathology report from July 2017 to December 2018 were extracted from PALGA, the nationwide network and registry of histo- and cytopathology in the Netherlands. PD-L1 positivity rates were determined for each laboratory that performed PD-L1 testing, with separate analyses for histological and cytological material. Two cutoffs (1% and 50%) were used to determine PD-L1 positivity. Differences between laboratories were assessed using funnel plots with 95% confidence limits around the overall mean.

Results

6,354 patients from 30 laboratories were included in the analysis of histology data. At the 1% cutoff, maximum interlaboratory variation was 39.1% (32.7%−71.8%) and ten laboratories (33.3%) differed significantly from the mean. Using the 50% cutoff, four laboratories (13.3%) differed significantly from the mean and maximum variation was 23.1% (17.2%−40.3%). In the analysis of cytology data, 1,868 patients from 23 laboratories were included. Eight laboratories (34.8%) differed significantly from the mean in the analyses of both cutoffs. Maximum variation was 41.2% (32.2%−73.4%) and 29.2% (14.7%−43.9%) using the 1% and 50% cutoffs, respectively.

Conclusion

Considerable interlaboratory variation in PD-L1 positivity was observed. Variation was largest using the 1% cutoff. At the 50% cutoff, analysis of cytology data demonstrated a higher degree of variation than the analysis of histology data.

Abbreviations

CCMO
Central Committee on Research involving Human Subjects
EMA
European Medicines Agency
EQA
external quality assessment
GDPR
General Data Protection Regulation
IHC
immunohistochemistry
LDT
laboratory-developed test
NSCLC
non-small cell lung cancer
PD-1
programmed death receptor-1
PD-L1
programmed death ligand-1
TCs
tumor cells
TPS
tumor proportion score

Keywords

Non-small cell lung cancer
Programmed death-ligand 1
Immunohistochemistry
Clinical pathology
Interlaboratory variation

Cited by (0)